Verona (VRNA) Talks Up The Long View Following Phase II Setback
Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower dose (1.5mg) in its phase II trial of RPL554, an [...]
Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower dose (1.5mg) in its phase II trial of RPL554, an [...]
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported impressive results on December 1, 2018 for its lymphoma drug candidate Selinexor, noting patients who experienced [...]
Last week, Galmed Pharmaceuticals (NASDAQ:GLMD) shares climbed as high as $9.90 per share this week, up approximately 7% on the [...]
Eidos Therapeutics, Inc. (NASDAQ:EIDX) shares are up as much as 17% today after the company reported positive phase II results [...]
November Catalyst: Aramchol SanaCurrents forecasts an advantageous probability Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will post positive results in an abstract report focused on [...]
4Q Catalyst: AG10 phase II data Based on its analytics score, SanaCurrents gives a superior sentiment rating that Eidos Therapeutics, [...]
Because FDA marketing clearance to sell a drug or device in the US remains the brass ring for medical manufacturers [...]
Introducing SanaCurrents Introducing SanaCurrents, a research service for the serious and sophisticated biotech investor. Founder of SanaCurrents, Bill Langbein, finally [...]